« Back to Directory of Resources
Treatments Under Development
Here you will find a list of current treatments under development:
| Brand Name: | ImMucin |
| Generic Name: | |
| Code Name: | |
| Company: | Vaxil BioTherapeutics |
| FDA Clinical Phase: | 1/2 |
Description:
ImMucin is a vaccine designed to stimulate the patient’s own …
| Brand Name: | |
| Generic Name: | |
| Code Name: | IPH 2101 (anti-KIR) |
| Company: | Innate Pharma |
| FDA Clinical Phase: | 1/2 |
Description:
IPH 2101 is a human antibody that helps activate cells of the immune system to destroy cancer cells. Specifically, IPH 2101 activates anti-tumor immune …
| Brand Name: | |
| Generic Name: | dacetuzumab |
| Code Name: | SGN-40 |
| Company: | Seattle Genetics Inc. |
| FDA Clinical Phase: | 1 |
Description
Dacetuzumab is a monoclonal antibody that specifically binds to and works against a molecule called a CD40 receptor, which appears in abnormally high amounts in …
| Brand Name: | |
| Generic Name: | ridaforolimus (formerly deforolimus) |
| Code Name: | AP23573 |
| Company: | Ariad Pharmaceuticals & Merck |
| FDA Clinical Phase: | 1 |
Description:
Ridaforolimus, formerly known as deforolimus, is …
| Brand Name: | |
| Generic Name: | |
| Code Name: | CX-4945 |
| Company: | Cylene |
| FDA Clinical Phase: | 1 |
Description:
CX-4945 is an oral anti-cancer agent. It inhibits CK2, an enzyme …
| Brand Name: | |
| Generic Name: | Marizomib, salinosporamide A |
| Code Name: | NPI-0052 |
| Company: | Triphase Research and Development I Corp |
| FDA Clinical Phase: | 1 |
Description:
Marizomib (NPI-0052, salinosporide A) (news articles) is a novel proteasome inhibitor that suppresses tumor growth by inhibiting the …